Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
VitaSpring Biomedical ( (VSBC) ) has provided an announcement.
VitaSpring Biomedical‘s CEO, Mr. Cheng-Hsiang Kao, and Chairman, Mr. Pao-Chi Chu, have been involved in various legal proceedings in Taiwan since August 2022. These cases involve allegations of unauthorized use of proprietary business know-how and intellectual property, with charges including violations of Taiwan’s Pharmaceutical Affairs Act, breach of fiduciary duty, and fraud. As of 2025, the legal matters are ongoing, with Mr. Chu acquitted in one case but facing an appeal. The company is monitoring the situation but does not anticipate a material adverse effect on its business.
More about VitaSpring Biomedical
Technical Sentiment Signal: Sell
Current Market Cap: $207M
For an in-depth examination of VSBC stock, go to TipRanks’ Overview page.